Literature DB >> 10554759

Trophoblastic pulmonary embolization after hysterectomy for invasive complete mole. A case report.

E I Garner1, W Y Chang-Lee, K H Lu, D P Goldstein, R S Berkowitz.   

Abstract

BACKGROUND: Trophoblastic pulmonary embolization usually occurs after evacuation of a molar pregnancy when the uterus is larger than dates and the human chorionic gonadotropin level is > 100,000 mIU/mL. It has a dramatic onset, with dyspnea, tachypnea, bilateral pulmonary infiltrates and low Po2 levels. Treatment requires supportive measures only. Intubation is rarely required. The clinical course is short-lived, with gradual improvement after 48 hours and complete resolution in 72 hours. There are no long-term sequelae. Differential diagnosis includes pulmonary embolization, fluid overload and aspiration. CASE: A 27-year-old, Caucasian woman, gravida 4, para 2, spontaneous abortion 1, developed presumed trophoblastic pulmonary embolization following abdominal hysterectomy for an invasive mole. The clinical course was typical of this condition, with spontaneous clearing in 72 hours with supportive measures only.
CONCLUSION: Trophoblastic pulmonary embolization can occur following abdominal hysterectomy for invasive mole as well as after molar evacuation and should be considered part of the differential diagnosis if patients present postoperatively with acute respiratory distress.

Entities:  

Mesh:

Year:  1999        PMID: 10554759

Source DB:  PubMed          Journal:  J Reprod Med        ISSN: 0024-7758            Impact factor:   0.142


  2 in total

1.  Comparison of different therapeutic strategies for complete hydatidiform mole in women at least 40 years old: a retrospective cohort study.

Authors:  Peng Zhao; Qinqing Chen; Weiguo Lu
Journal:  BMC Cancer       Date:  2017-11-09       Impact factor: 4.430

Review 2.  Acute trophoblastic pulmonary embolism during conservative treatment of placenta accreta: case report and review of literature.

Authors:  Qiu-Ming Wang; Hui-Li Liu; Qun Dang
Journal:  Eur J Med Res       Date:  2015-11-14       Impact factor: 2.175

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.